GC
TBPH icon

Guggenheim Capital’s Theravance Biopharma TBPH Stock Holding History

Guggenheim Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-7,349
Closed -$240K – 2362
2018
Q3 		$240K Buy
+7,349
New +$200K ﹤0.01% 2282
2015
Q2 		– Sell
-216,396
Closed -$3.75M – 3093
2015
Q1 		$3.75M Sell
216,396
-11,147
-5% -$204K 0.01% 1322
2014
Q4 		$3.4M Buy
227,543
+26,819
+13% +$467K 0.01% 1350
2014
Q3 		$4.63M Buy
200,724
+261
+0.1% +$7.57K 0.01% 1238
2014
Q2 		$6.39M Buy
+200,463
New +$6.03M 0.02% 1054

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Guggenheim Capital's TBPH Position: Q4 2018 in Review

Guggenheim Capital sold out of Theravance Biopharma (TBPH) in Q4 2018, closing a stake of 7,349 shares — an estimated $240K sold.

Guggenheim Capital first reported a position in TBPH in Q2 2014 and held it in 5 quarters. The position peaked at $6.39M in Q2 2014. 96 funds tracked by Wall St. Rank hold TBPH as of Q4 2018.

  • Guggenheim Capital reported no remaining Theravance Biopharma position as of Q4 2018 after selling out during the quarter.
  • Guggenheim Capital sold 7,349 Theravance Biopharma shares in Q4 2018, an estimated $240K.
  • Guggenheim Capital first reported a position in Theravance Biopharma in Q2 2014 and held it in 5 quarters.
  • Guggenheim Capital's Theravance Biopharma position peaked at $6.39M in Q2 2014.
  • 96 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2018.

Based on Guggenheim Capital's 13F filing for Q4 2018, filed 14 Feb 2019.